Fate Therapeutics Files 8-K for Charter Amendments
Ticker: FATE · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Fate Therapeutics filed an 8-K for charter amendments and fiscal year change.
AI Summary
On June 7, 2024, Fate Therapeutics, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation and changes to its fiscal year. The company, headquartered in San Diego, CA, operates in the biological products sector.
Why It Matters
This filing indicates potential structural or operational changes within Fate Therapeutics, which could impact its financial reporting and corporate governance.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose immediate financial or operational risks.
Key Numbers
- 001-36076 — SEC File Number (Identifies the company's filing history with the SEC.)
- 65-1311552 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- June 7, 2024 (date) — Date of earliest event reported
- San Diego, CA (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What specific amendments were made to Fate Therapeutics' Articles of Incorporation?
The filing indicates amendments were made, but the specific details of these amendments are not provided in this summary section of the 8-K.
What is the new fiscal year end for Fate Therapeutics?
The filing states there was a change in fiscal year, but the new end date is not specified in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 7, 2024.
Where are Fate Therapeutics' principal executive offices located?
Fate Therapeutics' principal executive offices are located at 12278 Scripps Summit Dr., San Diego, CA 92131.
What is Fate Therapeutics' Standard Industrial Classification (SIC) code?
Fate Therapeutics' SIC code is 2836, categorized under Biological Products (No Diagnostic Substances).
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-06-10 16:31:31
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share FATE The Nasdaq
Filing Documents
- d764437d8k.htm (8-K) — 25KB
- d764437dex31.htm (EX-3.1) — 7KB
- 0001193125-24-158374.txt ( ) — 154KB
- fate-20240607.xsd (EX-101.SCH) — 3KB
- fate-20240607_lab.xml (EX-101.LAB) — 18KB
- fate-20240607_pre.xml (EX-101.PRE) — 11KB
- d764437d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Fate Therapeutics, Inc. Date: June 10, 2024 By: /s/ J. Scott Wolchko Name: J. Scott Wolchko Title: President and Chief Executive Officer